Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 13,190,000 shares, an increase of 6.1% from the March 31st total of 12,430,000 shares. Based on an average daily volume of 849,900 shares, the short-interest ratio is presently 15.5 days.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in Citius Pharmaceuticals in the third quarter valued at $39,000. BNP Paribas Financial Markets grew its position in Citius Pharmaceuticals by 88.5% in the first quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after purchasing an additional 32,686 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Citius Pharmaceuticals in the third quarter valued at $76,000. Finally, Wealth Advisory Solutions LLC bought a new position in Citius Pharmaceuticals in the first quarter valued at $135,000. Institutional investors own 16.88% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Citius Pharmaceuticals in a report on Wednesday, February 14th.

Citius Pharmaceuticals Stock Down 2.7 %

Shares of CTXR stock opened at $0.73 on Thursday. The firm has a fifty day moving average of $0.79 and a 200-day moving average of $0.76. Citius Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $1.56. The company has a market capitalization of $115.55 million, a price-to-earnings ratio of -2.79 and a beta of 1.45.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Wednesday, February 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.19). On average, equities analysts expect that Citius Pharmaceuticals will post -0.21 EPS for the current year.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.